ERBB2 and breast cancer: The median overall survival for patients with metastatic triple‐negative breast cancer (TNBC) is approximately 12‐18 months, compared to 35‐55 months for HR‐positive/HER2‐negative breast cancer.5, 6, 7, 8, 9